Takashi Santou

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami et al. · ACS Medicinal Chemistry Letters · 2010 · 246 citations · Full text

Molecular Pharmacology, Pharmaceutical Science, Selective Gpr40 Agonist +12

Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists

Shinobu Sasaki, Shuji Kitamura, Nobuyuki Negoro et al. · Journal of Medicinal Chemistry · 2011 · 87 citations · Full text

Gpr40 Agonist Activity, Insulin Signaling, Metabolic Syndrome +16

Optimization of (2,3-Dihydro-1-benzofuran-3-yl)acetic Acids: Discovery of a Non-Free Fatty Acid-Like, Highly Bioavailable G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist as a Glucose-Dependent Insulinotropic Agent

Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami et al. · Journal of Medicinal Chemistry · 2012 · 73 citations · Full text

Glycobiology, Insulin Signaling, Metabolic Syndrome +22

Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonists

Nobuyuki Negoro, Shinobu Sasaki, Masahiro Ito et al. · Journal of Medicinal Chemistry · 2012 · 64 citations · Full text

Peptide Science, Pharmacotherapy, Insulin Signaling +18

Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach

Hiroshi Nara, Kenjiro Sato, Takako Naito et al. · Journal of Medicinal Chemistry · 2014 · 57 citations · Full text

Zinc Binding Group, Chemical Biology, Pharmaceutical Chemistry +20